The government has announced the COVID-19 vaccine clinical trial participants in England will be offered additional approved vaccine for international travel to countries which currently only accept vaccination records with approved for deployment COVID-19 jabs.
Although the UK recognises those who are in COVID-19 vaccine trials as fully vaccinated for the purpose of certification, most other countries do not currently recognise clinical trial volunteers who have not had a vaccine that is approved for deployment.
As such, the government will now offer these volunteers two additional doses of an approved vaccine, allowing them to gain the necessary certification status to travel abroad with more ease.
Initially, additional doses will be offered to participants taking part in the Novavax clinical trial, which includes the majority of those in ongoing trials for vaccines not yet approved for deployment.
On top of that, people who have received two doses of a vaccine as part of a clinical trial will also be offered a booster dose, if eligible.
“The measures we have taken will allow UK COVID-19 vaccine trial participants to travel freely overseas once they have had the additional vaccinations. Those volunteers now have the flexibility to make a decision for themselves so they can, for example, visit loved ones abroad,” said professor Jonathan Van-Tam, deputy chief medical officer for England.
“We should be very clear that the results from these trials benefit the whole world, and it has to be said that if more countries around the world had reciprocated by allowing UK volunteers to enjoy fully vaccinated status for overseas travel, these measures would not have been necessary,” he added.